3 Undervalued Healthcare Stocks Invstors Can Buy Right Now

The article argues that investors' focus on artificial intelligence may be causing the healthcare sector to be overlooked, highlighting Eli Lilly as the stock under consideration. It provides no new earnings, valuation, drug-development, or operating metrics for Eli Lilly, and the bulk of the text is promotional material for Motley Fool's Stock Advisor service.

Analysis

This is not investable fundamental research; it is promotional content with no new prescribing, reimbursement, trial, utilization, or earnings evidence. The negative LLY signal is therefore more likely an index of retail-attention rotation than a change in the obesity franchise’s intrinsic outlook. Do not infer a healthcare re-rating from reduced AI enthusiasm alone: LLY’s multiple remains primarily a function of GLP-1 volume, net price, manufacturing throughput, and the durability of its lead versus NVO and emerging oral competitors.

The more actionable second-order question is whether incremental capital leaving AI leaders seeks defensive earnings visibility or merely reduces broad-market risk appetite. In a modest rotation, profitable large-cap pharma and managed care can outperform high-duration semis; in a macro de-risking, both can fall, with richly valued growth healthcare vulnerable to multiple compression. TDOC should not be used as a healthcare-beta proxy: its equity outcome is driven by membership trends, BetterHelp stabilization, and sustained EBITDA/FCF conversion rather than sector flows.

Over the next 1-3 months, monitor LLY prescription-data momentum, supply-related commentary, PBM formulary decisions, and any change in obesity-treatment net pricing. Over 6-18 months, the key falsifier for a constructive LLY view is evidence that capacity additions fail to translate into incremental treated patients or that competition compresses realized price faster than volume grows; absent those data, this article alone warrants no directional position.

Key Decisions for Investors

• No trade on the article. Maintain LLY as a watch item rather than adding exposure until independent weekly prescription trends and the next earnings update confirm volume growth is outpacing net-price pressure.
• For a tactical sector-rotation expression only after confirming sustained relative-strength reversal, consider long XLV versus short SMH over a 1-3 month horizon; use a tight stop if SMH reclaims relative highs, as renewed AI capex guidance would quickly invalidate the rotation thesis.
• Avoid treating TDOC as a defensive healthcare substitute. Reassess only if quarterly revenue retention, BetterHelp trends, and free-cash-flow guidance show a durable inflection; without that evidence, downside from execution risk can dominate any sector allocation benefit.
• For existing LLY exposure, define a catalyst checklist for the next earnings cycle: raised volume guidance, stable/improving gross-margin outlook, and no adverse formulary or reimbursement surprise. A guidance cut tied to realized pricing or supply normalization would warrant reducing exposure regardless of broader healthcare sentiment.